As part of a multidisciplinary team, clinical pharmacists identified systemic lupus erythematosus (SLE) as an IFN-α2b related ADR and provided individual treatment regimens and dosages to physicians according to the patient’s age, liver function, risk of infection, renal injury indicators, extrarenal organ injury, fertility intention, comorbidities, and response to treatment with previous immunity inhibitors. This evidence concerns the gene IFNA2 and systemic lupus erythematosus.